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Due to significant differences in healthcare structure between the United States and Canada, there are unique
barriers to adopting new medical technology in Canada. In this article, we describe our experience developing a
transoral robotic surgery (TORS) program at Western University. Specifically, we outline the steps that were
necessary to obtain institutional and multidisciplinary team approval, financial support, as well as surgeon and allied
healthcare personnel training. This experience can potentially be used as a roadmap for other Canadian institutions
pursuing a TORS program.
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Head and neck squamous cell carcinoma (HNSCC) is
the fifth most common cancer in Canada, affecting more
than 4500 Canadians each year [1]. Despite a national
decrease in rates of alcohol and tobacco use, there has
been an epidemic rise in the incidence of one subset of
HNSCC - cancers arising from the oropharynx [2,3].
Over the last three decades, oropharyngeal cancers have
tripled, an increase now known to be due to oral infec-
tion with the human papillomavirus (HPV) [3,4]. At
many institutions, chemoradiation is the standard of
care. However it carries significant short and long
term side effects, such as mucositis, fibrosis, dysphagia,
xerostomia, and tissue necrosis [5-7]. These results have
led the oncology community to reconsider surgical
approaches in a minimally invasive context. Since recei-
ving FDA approval in 2009, transoral robotic surgery
(TORS) for the treatment of T1-2 oropharyngeal and la-
ryngeal cancers has become rapidly adopted at many
institutions in the United States. The initial results of
many small studies suggest that this surgical approach
provides excellent survival rates and superior speech and* Correspondence: Anthony.Nichols@lhsc.on.ca
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reproduction in any medium, provided the orswallowing outcomes relative to other organ preserva-
tion approaches [8-10]. However, prior to December
2010 a TORS program had not been developed in
Canada. Delayed adoption of this promising technology
is at least in part due to the disparate healthcare systems.
The aim of this article is to describe the development of
a TORS program in Canada, highlighting the challenges
that needed to be overcome, some of which are unique
to a universal healthcare system.Process of introducing TORS at the London health
sciences centre
Multidisciplinary team collaboration and evidence based
treatment planning
Treatment of all head and neck cancer patients at the
London Regional Cancer Centre is conducted within the
framework of the Cancer Care Ontario guidelines [11].
Treatment recommendations are by consensus of our
multidisciplinary team including radiation oncologists,
medical oncologists, and head and neck surgeons. To
implement any significant changes to the treatment
practices of our institution, we required the approval of the
multidisciplinary team. We therefore began with a multi-
disciplinary journal club to review the relevant literature
regarding transoral resection and chemoradiation in an
attempt to compare the results of the two treatments.
These discussions were supplemented by educational visitsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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developing TORS programs at their respective institutions.
One clinical expert was a radiation oncologist with exten-
sive experience in providing post-operative radiation for
patients who have undergone a TORS procedure. He out-
lined the treatment fields he used in order to de-intensify
post-operative radiation and highlighted the excellent func-
tional outcomes that had been achieved including low
gastrostomy tube (G-tube) rates of approximately 2%
[8-10]. The second expert was a head and neck surgeon
who has utilized TORS for over five years.
After several discussions, a protocol meeting was
arranged to discuss the possible integration of TORS into
our current treatment algorithms. Our review of current
practices revealed that following FDA approval, many cen-
ters in the United States began using TORS as the preferred
modality of treatment for oropharyngeal and laryngeal
cancer including those with advanced regional metastases.
The majority of these patients still require post-operative
adjuvant therapy [8-10]. In order to select for patients who
could avoid adjuvant therapy entirely, our consensus was to
adopt a more conservative approach, offering surgery to
selected stage I-II oropharyngeal and supraglottic cancers.
Other eligible patients include those with absolute surgical
indications, such as T1-2 radiation failures and small sali-
vary gland tumors, where the treatment alternative would
traditionally require open surgery. We also developed
evidence-based guidelines for post-operative chemotherapy
and radiation following TORS.
Institutional approval
In order to obtain ethical and administrative approval for
TORS there were a number of challenges that had to be
overcome related to the novelty of treatment, costs, and
operating room requirements. The Canadian Surgical
Technologies & Advanced Robotics (CSTAR) Centre, an
organization that supports all minimally invasive surgery
(MIS) research at our institution, played an important role
in facilitating the approval of this pilot project. CSTAR pro-
vides ethical review and funding for approved projects in
order to help overcome the unique difficulties in generating
research in the field of MIS in Canada. This organization
has established a formal application process for new proce-
dures that requires certificates of training, a description of
the procedure in question, study designs that include
patient outcome measures, and a budget calculated with a
cost per case assessment. After a formal review by the MIS
Committee, our application was approved.
Training/Certification
Presently, there are only three TORS training programs in
North America, located in Philadelphia, Pennsylvania;
Sunnyvale, California; and Houston, Texas. These sites offer
one-week certified programs that include animal, cadavericand observational training for head and neck surgeons.
Access to these training programs can be challenging as
there is an excess of demand with only a limited number of
training spots. Moreover, the producers of the da Vinci
robot, Intuitive Surgical, Inc., have partial oversight of the
selection of surgeons accepted into the program. Intuitive
Surgical, Inc. has set strict criteria for entry including evalu-
ation of the institution and surgeon’s case volumes, access
to a robot and the ability of the surgeon to perform the first
robotic procedure within 2 weeks of course completion.
This last requirement can be particularly challenging due to
the short time frames involved with treating patients with
HNSCC. Ultimately, two Head and Neck surgeons from
the London Health Sciences Centre (ACN and KF) were
accepted in to the program and completed training at the
University of Pennsylvania.
Study design
The multidisciplinary team stressed the importance of pro-
spective trials and to collect follow-up data on specific sur-
gical and quality of life outcome measures. Subsequently,
we delineated outcome measures for our preliminary ex-
perience including margin status, blood loss, complication
rates, gastric tube rates and post-operative days in hospital.
Other outcome metrics included functional and quality of
life (QOL) outcomes such as validated QOL questionnaires,
modified barium swallows, and vocal acoustic analysis
[12-14]. These tests would be administered pre-operatively
and at three, six and 12 months post-operatively.
Funding and hospital resources required
The cost of da Vinci robot and its maintenance is signifi-
cant (Table 1). The cost of the new SI version of the
robot is $2.5 million. In addition, there are annual main-
tenance fees and costs for disposable instruments used
in each case. In the United States insurance providers do
not cover the additional cost incurred by the robotic
components, so the institution must absorb it. This cost
is recouped by capturing additional patients by this
high-profile technology. Increased patient volume results
in greater use of hospital services and consultations, and
subsequently increased institutional revenues.
In Canada, this strategy is incompatible with our health-
care system hospital funding structure. With hospitals
placing a premium on cost-containment, there is no finan-
cial incentive for patient recruitment. Among the priorities
of the London Health Sciences Centre has been to evaluate
technological advances, especially in the field of minimally
invasive surgical (MIS) care. Our institution in conjunction
with private donors established funding for MIS initiatives,
which enabled the purchase of the necessary capital
and disposable instruments. The average cost per case
of expendable equipment is $857.02 USD (See Table 1
for a cost breakdown). Since the da Vinci Robot is used at
Table 1 Cost of da Vinci robot purchase, annual maintenance and, initial and per case costs specific to trans-oral
robotic surgery
Expenditure Costs specific to trans-oral surgery cases Costs of operating the da Vinci Robot••
Initial costs Cost per case• Initial cost Annual cost
da Vinci-SI robot $2,500,000.00
Maintenance Contract $112,000.00
FK Retractor (Olympus) $10,735.00
Maryland Dissector (20 uses) $7,106.00 $355.30
Cautery Instrument (18 uses) $6,394.00 $355.22
Cautery Spatula Tip (10) $1,465.00 $146.50
Total $25,700.00 $857.02 $2,500,000.00 $112,000.00
• Costs per case specific to TORS as quoted by Minogue Medical 2010:
•• Costs of purchasing and maintaining the da Vinci Robot system were not specific to TORS procedures and thus were not incurred by the head and
neck department.
Table 2 da Vinci Robot Sites in Canada
Institution Robot model
CHUM - St. Luc (Montreal) Si
Hôpital du Sacré-Cœur de Montréal Standard
Humber River Regional Hospital (Toronto) Si
Jewish General Hospital (Montreal) S
London Health Sciences Center Si
Montreal General Hospital Si
RockyView Hospital (Calgary) Si
Royal Alexandra Hospital (Edmonton) S
St. Joseph’s Hospital (Hamilton) Si
St. Michaels Hospital (Toronto) S
The Ottawa Hospital Si
Toronto General Hospital S
University of Alberta Hospital (Edmonton) S
Vancouver General Hospital S
Information obtained from Minogue Medical Inc.
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maintenance costs of the robot were not borne by the
Otolaryngology-Head and Neck Surgery department.
Once diagnosed, HNSCC needs to be treated within a
short time frame (one to three weeks) in contrast to other
robotic procedures that can be completed on a less urgent
basis. This is particularly true in the oropharynx and larynx
where tumour growth can change the extent of surgery,
which in turn can affect oncologic and functional out-
comes. Thus once a case is identified, access to the surgical
robot must be available within a reasonable time frame. We
worked closely with hospital leadership to obtain assu-
rances that all cancer cases could be completed within two
weeks of the decision to proceed with surgery.
Collaboration with anaesthesia
Like other upper aerodigestive tract surgeries, airway man-
agement remains critical to the welfare of the patient and is
facilitated through effective communication between the
surgeon and the anaesthesiologist. Unlike open surgery,
patients undergoing TORS do not typically require a
tracheostomy [10]. However, airway management was dis-
cussed with the anaesthesia service in a preliminary meet-
ing to ensure adequate precautions would be taken with
these patients. Airway considerations are reviewed with the
consultant anaesthesiologist prior to each case. Specific
recommendations were made with respect to pre-operative
steroid use, the use of an un-taped armoured endotracheal
tube, and continuous post-operative pulse oxygenation
monitoring.
Nursing and allied health education
A great deal of effort was undertaken to ensure adequate
nursing and allied heath team training to support the TORS
program. Educational materials and training sessions were
provided in the pre-operative clinic and on the floor. Pre-
operative considerations included patient counseling and
arranging consultations with anesthesia and medicine.Post-operative nursing care education emphasized airway
concerns, bleeding risk, and speech and swallowing evalu-
ation. For operating room nurses, a full day training session
was coordinated. In addition, a Minogue Medical (distribu-
tor of the da Vinci robot in Canada) biomedical engineer is
present for all cases to assist with technical difficulties and
provide further training.
Developing a transoral robotic surgery program at other
Canadian institutions
There are 13 Canadian hospitals that have da Vinci surgi-
cal robots and thus the potential to start a TORS program
(Table 2). There are three models including the Standard,
S and Si. The S and Si are ideal for TORS due to the lower
profile arms which allow easier access to the oral cavity.
All the above mentioned institutions in collaboration
with Minogue Medical have developed a rigorous cre-
dentialing process to ensure safe implementation of all
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process include completion of the surgeon clinical pathway
(training course), appropriate surgeon and nursing onsite
training, appointment of a robotic coordinator with the
appropriate training, and facilities for instrument cleaning
and sterilization. Currently the University of Ottawa is
following this pathway with the goal of starting their TORS
program in early 2013.
Future directions
To date, the oncologic and functional outcomes of TORS
have been encouraging. However, this technology has not
been evaluated in randomized controlled trials. We have re-
cently opened a phase II randomized trial of primary TORS
versus radiation for early stage oropharyngeal cancer
named ORATOR (Carcinoma of the Oropharynx: Radi-
ation versus Transoral Robotic Surgery) that is funded by
the Canadian Cancer Society [15]. This study is powered to
detect a clinically significant superior swallowing outcome
in the TORS arm using the MD Anderson dysphagia inven-
tory (MDADI) [13]. In addition, there are two multi-
centred trials being planned in the United States through
the ECOG and RTOG cooperative groups studying HPV-
positive and negative oropharyngeal cancer, respectively.
This level of evidence is necessary for ultimate validation of
this surgical approach and broader adoption in Canada and
beyond.
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